After 15 Years, First New Recombinant Coagulation Facto...
October 1, 2013 - Clinical By: Tamara Yunusova, Senior Staff Editor – After a lengthy fifteen-year hiatus in recombinant drug approvals, FDA-approved Recombinant Coagulation Factor IX (Rixubis) has mounted to the forefront of Hemophilia B drug therapy. The recombinant coagulation factor gained orphan drug approval on June 26, 2013 for routine prophylaxis, control of bleeding episodes, and perioperative management in… |
|
BRAIN Initiative: Mapping the Human Brain...
October 1, 2013 - Featured , In the News / Politics By Erica Dimitropoulos, Senior Staff Editor – If you were in charge of government spending, how would you allocate our funds? Would you put more money into public schools? Restructure the healthcare system? How about a multi-billion dollar project to remap the brain? A few months ago, President Obama announced his plans to invest in… |
|
Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily… |
|
Hope For Children with Acute Lymphoblastic Leukemia...
October 1, 2013 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Emily Whitehead, a 7-year-old girl who fought off relapsing acute lymphoblastic leukemia (ALL), has captured the hearts and prayers of the masses. Her story is an inspiration to those battling any disease with a poor prognosis and particularly holds promise for the 15% of children with ALL resistant to… |
|
Ketoconazole No More...
October 1, 2013 - Featured , In the News / Politics By: Hayeon Na, Co-Copy Editor [Content-Focused] – The Food and Drug Administration (FDA) announced on July 26th that oral dosage forms of ketoconazole (Nizoral®) should no longer be prescribed as first-line therapy for any fungal infections.1 The label and indication for oral ketoconazole were updated, and a new medication guide was added. Other dosage forms… |
|
Meet the Dean: Interview with Dean DiGate...
October 1, 2013 - Featured , Professional Advice / Opinions By: Katharine Cimmino, Editor-in-Chief and Erica Dimitropoulos, Senior Staff Editor – Just last month, St. John’s University College of Pharmacy and Health Sciences kindly welcomed a new Dean into our family, Dean Russell J. DiGate. Dean DiGate is a highly experienced educator and academic leader. He attended the University of Rochester, where… |
|
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
|
New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to… |
|
New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who… |
|
What You Should Know About Selecting APPE Rotations...
October 1, 2013 - Professional Advice / Opinions By: Aleena Cherian, Co-Copy Editor, Graphics Focused – Selecting APPE Rotations You’ve made it past the progression interviews at the end of 2nd year, the White Coat Ceremony, and the mind-boggling compounding and kinetics equations. You’re almost done with those labs and late night D&D study sessions. Now, halfway through the first semester of your… |